Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 6, 2010, Pages 755-769

  Geiler, Janina ^a   McDermott, Michael F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIGUANIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; EXENDIN 4; GEVOKIZUMAB; IMMUNOGLOBULIN G2; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; LIRAGLUTIDE; METHOTREXATE; MONOCLONAL ANTIBODY; OTELIXIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TEPLIZUMAB; UNCLASSIFIED DRUG; VILDAGLIPTIN; XOMA 052;

ABSENCE OF SIDE EFFECTS; ARTICLE; AUTOINFLAMMATORY DISEASE; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SYNTHESIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; HUMAN; IC 50; IMMUNE RESPONSE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD; MUCKLE WELLS SYNDROME; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INTERLEUKIN-1BETA; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 79952969400     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (145)

1. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BResnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I et al Arthritis Rheum 1998 41 12 2196-2204 (Pubitemid 29009378) (Pubitemid 29009378)
2. The role of the interleukin-1-receptor antagonist in blocking infammation mediated by interleukin-1. Dinarello CA N Engl J Med 2000 343 10 732-734
3. Cytokine imbalance in the pathoGenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Arend WP SEMIN ARTHRITIS RHEUM 2001 30 5 Suppl 2 1-6 (Pubitemid 32467129) (Pubitemid 32467129)
4. A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Guler HP, Caldwell J, Littlejohn T, McIlwain H, Offenberg H, Stahl N ARTHRITIS RHEUM 2001 44 9 Suppl Abs 1907
5. Cytokine traps: Multi-component, high-affnity blockers of cytokine action. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP et al NAT MED 2003 9 1 47-52 (Pubitemid 36098259) (Pubitemid 36098259)
6. Type 1 diabetes: New perspectives on disease pathoGenesis and treatment. Atkinson MA, Eisenbarth GS Lancet 2001 358 9277 221-229 (Pubitemid 32718550) (Pubitemid 32718550)
7. Insulin needs after CD3-antibody Therapy in new-onset type 1 diabetes. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L et al N Engl J Med 2005 352 25 2598-2608 (Pubitemid 41007846) (Pubitemid 41007846)
8. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) Results in improvement in C-peptide Responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, RoTher K, Diamond B, Harlan DM, Bluestone JA DIABETES 2005 54 6 1763-1769 (Pubitemid 40770766) (Pubitemid 40770766)
9. XOMA reports third quarter 2005 fnancial Results; highlights: Multiple myeloma phase I with Chiron, new Cubist contract and BCE licenses. XOMA Ltd Press Release 2005 November 02
10. The comparative effcacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and meta analysis. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN J RHEUMATOL 2006 33 12 2398-2408 (Pubitemid 46067817) (Pubitemid 46067817)
11. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY N Engl J Med 2007 356 15 1517-1526 (Pubitemid 46588416) (Pubitemid 46588416)
12. XOMA initiates phase I U.S. trial in type 2 diabetes for XOMA 052, monoclonal antibody with Therapeutic potential in multiple infammatory diseases. XOMA Ltd Press Release 2007 July 16
13. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monoTherapy on glycemic control in patients with type 2 diabetes. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin SG DIABETES CARE 2006 29 12 2632-2637 (Pubitemid 44912190) (Pubitemid 44912190)
14. New CIAS1 mutation and anakinra effcacy in overlapping of Muckle-Wells and familial cold autoinfammatory syndromes. Maksimovic L, Stirnemann J, Caux F, Ravet N, Rouaghe S, Cuisset L, Letellier E, Grateau G, Morin AS, Fain O RHEUMATOLOGY 2008 47 3 309-310 (Pubitemid 351267196) (Pubitemid 351267196)
15. XOMA reports frst quarter 2008 fnancial Results. XOMA Ltd Press Release 2008 May 12
16. Effcacy of XOMA 052 anti-IL-1 antibody in the DBA/1 mouse collagen-induced arthritis model. Owyang A, Esposito L, Vanegas S, Masat L, Pongo E, Larsen P, Corbin J, Ahluwalia K, Roell M, Horwitz A, Haak-Frendscho M et al Clin IMMUNOL 2008 127 Suppl S1 Abs Sa.56
17. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GGL, Houser JE, QuReshi IZ, Ownby ED, Gustini E et al Circulation 2008 117 20 2670-2683
18. Effects of abatacept in patients with methotrexate-Resistant active rheumatoid arthritis: A randomized trial. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge ZY, Becker JC, Westhovens R Ann Intern Med 2006 144 12 865-876 (Pubitemid 46768126) (Pubitemid 46768126)
19. The human anti-IL-1 monoclonal antibody ACZ885 is effective in joint infammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJM, Woodworth TG et al ARTHRITIS Res Ther 2008 10 3 R67-R75
20. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant Therapy with traditional disease modifying antirheumatic Drugs: Evidence from the OMEGA trial. Le Loet X, Nordstrom D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JMGW, Woolley JM, Wright N, Lawrence C, Appleton B J Rheumatol 2008 35 8 1538-1544
21. XOMA 052 clinical Results support new type 2 diabetes Therapeutic approach of targeting infammatory damage to insulin-producing cells. XOMA Ltd Press Release 2008 September 08
22. XOMA 052, an anti-IL-10 antibody, in a double-blind, placebo controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus-A new approach to Therapy. Donath MY, Weder C, Whitmore J, Bauer RJ, Der K, Scannon PJ, Dinarello CA, Solinger AM Diabetologia 2008 51 Suppl 1 Abs 1
23. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monoTherapy: A 48-week, comparative, prospective study. Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, Kaskani E, Sfikakis PP RheumatolOGY 2008 47 9 1384-1388
24. Efficacy of XOMA 052 anti-IL-10 antibody in the DBA/1 mouse collagen-induced arthritis model. Owyang AM, Esposito L, Vanegas S, Gross L, Masat L, Corbin J, Roell M, Horwitz A, Haak-Frendscho M, Kantak S Arthritis Rheum 2008 58 9 Suppl Abs 264
25. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J Ann Rheum Dis 2008 67 11 1516-1523
26. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate Response to disease-modifying antirheumatic Drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic Drug Therapy study. Genovese MC, Mckay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Rein JJ Arthritis Rheum 2008 58 10 2968-2980
27. XOMA provides clinical plan update on diabetes Drug candidate. XOMA Ltd Press Release 2008 December 10
28. XOMA initiates phase 2a clinical trial with XOMA 052 in patients with rheumatoid arthritis. XOMA Ltd Press Release 2009 March 04
29. XOMA reports 2008 financial Results. XOMA Ltd Press Release 2009 March 11
30. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B Diabetes Care 2009 32 1 193-203
31. XOMA 052, a potential disease modifying anti-IL-1β antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 Diabetes. Donath M, Weder C, Brunner A, Keller C, Whitmore J, Der K, Zayed H, Scannon PJ, Feldstein JD, Dinarello CA, Solinger AM Diabetes 2009 58 Suppl 1 Abs 113-OR
32. XOMA 052, an anti-IL-1β antibody, improves glucose control, β-cell function, and insulin Resistance in the diet-induced obesity mouse model. Owyang AM, Gross L, Yin J, Lee S, Shu L, Bergemann J, Jadhav J, Esposito L, Maedler K, Kantak S Diabetes 2009 58 Suppl 1 Abs310-OR
33. Use of canakinumab in the cryopyrin-associated periodic syndrome. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN N Engl J Med 2009 360 23 2416-2425
34. XOMA 052 clinical Results support novel anti-inflammatory approach to type 2 Diabetes treatment. XOMA Ltd Press Release 2009 June 06
35. Video: New biological Therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease. Novartis AG Press Release 2009 June 18
36. XOMA 052, a monoclonal antibody that regulates interleukin-1β (IL-1β) activity: An example of a new class of regulatory antibody Drugs that may confer a unique advantage in the treatment of type 2 Diabetes mellitus. Roell MK, White M, Issafras H, Michelson K, Vanegas S, Gross L, Lee S, Mirza A, Hunter J, Corbin J, Kantak S et al Diabetologia 2009 52 Suppl 1 Abs 370
37. XOMA reports 2009 third quarter financial Results. XOMA Ltd PRes Release 2009 November 09
38. XOMA 052, a regulatory monoclonal antibody targeting IL-1β, reduces biomarkers of cardiovascular risk in animal models. Bhaskar V, Owyang A, Lee S, Gross L, Yin J, Solinger A, Zayed H, Kantak S, Scannon P, Doberstein SK Cytokine 2009 48 1-2 77-78
39. Nonclinical safety evaluation of XOMA 052, a monoclonal antibody targeting IL-1β, in 4-and 13-week repeat-dose toxicity studies in cynoMolgus monkeys. Meyer K, Der K, Ma J, Espinoza Y, Cao LC, Gasper C, Bauer R, Bechtel C, Tichenor S Int J Toxicol 2009 28 1 Abs P43
40. Alcon independent director committee says company's Q4/FY 2009 financial Results underscore gross inadequacy of Novartis' proposal to minority shareholders. Alcon Inc Press Release 2010 February 12
41. XOMA 052 phase 2 trial initiated in type 1 Diabetes patients. XOMA Ltd Press Release 2010 March 12
42. NCT00998699: Study of the effects of XOMA 052 on insulin production in subjects with well controlled type 1 Diabetes. XOMA Ltd; University of Zurich CLINICALTRIALS.GOV 2009
43. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline Residual β cell mass. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S et al Diabetologia 2010 53 4 614-623
44. A novel humanized anti-IL-1β antibody is highly effective at inhibiting IL-1 induced IL-6 production in myeloma patients in vitro. Lust J, Moon-Tasson L, Solinger A, Donovan K AM Assoc Cancer Res Ann Meet 2010 101 April 19 Abs 2449
45. Kinetic approach to pathway attenuation using XOMA 052, a regulatory Therapeutic antibody that modulates interleukin-1β activity. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, Bohmann DJ, Nonet GH et al J Biol Chem 2010 285 27 20607-20614
46. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, Van Vollenhoven RF, Li NF, Agarwal S, Hessey EW et al Arthritis Rheum 2006 54 5 1390-1400
47. Safe, rapid-onset, and sustained biological activity of IL-1β regulating antibody XOMA-052 in Resistant uveitis of Behcet's disease: Preliminary Results of a pilot trial. Gul A, Artim Esen B, Solinger A, Giustino L, Tugal Tutkun I Annu Eur Congr Rheumatol 2010 69 Suppl 3 178
48. Positive clinical findings pResented on XOMA 052 in debilitating eye disease. XOMA Ltd Press Release 2010 June 17
49. Combination studies of the anti-interleukin-1β monoclonal antibody XOMA 052 with exendin-4 or sitagliptin in a diet-induced obesity mouse model of type 2 Diabetes mellitus. Lee S, Owyang AM, Gross L, El Bader S, Yin J, Bhaskar V, Maedler K, Kantak S Diabetes 2010 59 Suppl 1 Abs 1811-P
50. Inhibition of interleukin-1β with the monoclonal antibody XOMA 052 reveals the differential sensitivities of glycemic and pancreatic function parameters to chronic inflammation. Owyang AM, Lee S, Gross L, Phan D, Yin J, El Bader S, Bhaskar V, Maedler K, Mirza A, Kantak S Diabetes 2010 59 Suppl 1 Abs 1820-P
51. XOMA 052, an anti-IL-1β monoclonal antibody, improves glucose control and β-cell function in the diet-induced obesity mouse model. Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, Jadhav J, Domsgen E, Bergemann J, Lee S, Kantak S Endocrinology 2010 151 6 2515-2527
52. NCT01066715: Safety and efficacy of XOMA 052 in subjects with type 2 Diabetes mellitus on stable metformin monoTherapy. XOMA Ltd CLINICALTRIALS.GOV 2010
53. A 26-week repeat-dose toxicity study in cynoMolgus monkeys with XOMA 052, a novel monoclonal antibody targeting IL-1β. Meyer K, Der K, Ma J, Espinoza Y, Cao LC, Gasper C, Bechtel C Int J Toxicol 2010 29 1 Abs P5
54. High affinity humanized monoclonal antibody to human IL 1β potently inhibits toll-like receptor (TLR) agonists in whole Blood. Reznikov L, Solinger A, Dinarello C J Immunol 2007 178 Abs B61
55. Preclinical use of population pharmacokinetics for XOMA 052, a recombinant human engineered monoclonal antibody, in cynoMolgus monkeys. Der KR AAPS NATL Biotechnol Conf 2008 Abs M1008
56. XOMA 052, an anti-IL-1β antibody, pReserves β-cell function and reduces hyperglycemia in the diet-induced obesity mouse model of type 2 Diabetes. Owyang AM, Gross L, Shu L, Esposito L, Maedler K, Kantak S Diabetes 2008 57 Suppl 1 Abs 75-LB
57. XOMA 052, a potential disease-modifying antiinterleukin-1 β (IL-1 β) regulatory antibody, shows reductions in hs-CRP, HbA1C and FPG after subcutaneous injection in a randomized, blinded, placebo-controlled trial in subjects with type 2 Diabetes mellitus. Feldstein JD, Urquilla PR, Der K, Zayed H, Guzy S, Maurer AF, Whitmore J, Hansen RK, Scannon PJ World Diabetes Congress 2009 20 Abst D-0856
58. XOMA website. XOMA Ltd COMPANY World WIDE WEB SITE 2010 July 16
59. Drug datasheet: Arcalyst. ReGeneron Pharmaceuticals Inc Drug DATASHEET WEBSITE 2010 June
60. Diabetes. World Health Organization COMPANY World WIDE WEB SITE 2009 November Fact Sheet No 312
61. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G Arthritis Rheum 2003 48 4 927-934 (Pubitemid 36418234) (Pubitemid 36418234)
62. Sensing pathogens and danger signals by the inflammasome. Pedra JHF, Cassel SL, Sutterwala FS Curr Opin Immunol 2009 21 1 10-16
63. Cytokine production by islets in health and Diabetes: Cellular origin, regulation and function. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA Trends Endocrinol Metab 2010 21 5 261-267
64. IL-1β processing in host defense: Beyond the inflammasomes. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JWM, Joosten LAB Plos Pathogens (Online) 2010 6 2 e1000661
65. Glucose promotes the production of interleukine-1β and cyclooxygenase-2 in mesangial cells via enhanced (pro)renin receptor expRession. Huang J, Siragy HM Endocrinology 2009 150 12 5557-5565
66. Prediction and pathoGenesis in type 1 Diabetes. Ziegler AG, Nepom GT Immunity 2010 32 4 468-478
67. An update on preventive and reGenerative Therapies in Diabetes mellitus. Reimann M, Bonifacio E, Solimena M, Schwarz PEH, Ludwig B, Hanefeld M, Bornstein SR Pharmacol Ther 2009 121 3 317-331
68. Low concentration of interleukin-1β induces FLICEinhibitory protein-mediated β-cell proliferation in human pancreatic islets. Maedler K, Schumann D, Sauter N, Ellingsgaard H, Bosco D, Baertschiger R, Iwakura Y, Oberholzer J, Wollheim CB, Gauthier BR, Donath MY Diabetes 2006 55 10 2713-2722 (Pubitemid 44923669) (Pubitemid 44923669)
69. Blockade of interleukin 1 in type 1 Diabetes mellitus. Mandrup-Poulsen T, Pickersgill L, Donath MY Nat Rev Endocrinol 2010 6 3 158-166
70. Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK Mediators INFLAMM 2006 2006 1 59206
71. Interleukin-1 stimulates β-cell necrosis and release of the Immunological adjuvant HMGB1. Steer SA, Scarim AL, Chambers KT, Corbett JA Plos Med (Print) 2006 3 2 253-266
72. Rituximab, B-lymphocyte depletion, and pReservation of β-cell function. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P et al N Engl J Med 2009 361 22 2143-2152
73. The role of T-cells in the pathoGenesis of type 1 Diabetes: From cause to cure. Roep BO Diabetologia 2003 46 3 305-321 (Pubitemid 36547585) (Pubitemid 36547585)
74. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. Hollander GA, Bierer BE, Burakoff SJ Transfus Sci 1994 15 3 207-220
75. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Dupre J, Kolb H Diabetes 1988 37 11 1574-1582
76. Metabolic and Immunological effects of cyclosporin in recently diagnosed type 1 Diabetes mellitus. Assan R, Feutren G, Debray-Sachs M, Quiniou-Debrie MC, Laborie C, Thomas G, Chatenoud L, Bach JF Lancet 1985 1 8420 67-71 (Pubitemid 15189820) (Pubitemid 15189820)
77. Cyclosporin and methotrexate Therapy induces remission in type 1 Diabetes mellitus. Sobel D, Henzke A, Abbassi V Acta Diabetol 2010 47 3 243-250
78. The role of interleukin-1 in the pathoGenesis of IDDM. Mandrup-Poulsen T Diabetologia 1996 39 9 1005-1029 (Pubitemid 26275930) (Pubitemid 26275930)
79. Increased monocytic activity and biomarkers of inflammation in patients with type 1 Diabetes. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I Diabetes 2006 55 3 774-779 (Pubitemid 43343235) (Pubitemid 43343235)
80. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, Irminger JC, Kergoat M Portha B, Homo-Delarche F, Donath MY Proc Natl Acad Sci USA 2009 106 33 13998-14003
81. Immunological and inflammatory functions of the interleukin-1 family. Dinarello CA Annu Rev Immunol 2009 27 519-550
82. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 Diabetes. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T Diabetes Care 2009 32 9 1663-1668
83. An immune origin of type 2 Diabetes. Kolb H, Mandrup-Poulsen T Diabetologia 2005 48 6 1038-1050
84. Is type II Diabetes mellitus a disease of the innate immune system? Pickup JC, Crook MA Diabetologia 1998 41 10 1241-1248 (Pubitemid 28449093) (Pubitemid 28449093)
85. β-cell deficit and increased β-cell apoptosis in humans with type 2 Diabetes. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC Diabetes 2003 52 1 102-110 (Pubitemid 36042113) (Pubitemid 36042113)
86. The life story of the pancreatic B cell. Hellerstrom C Diabetologia 1984 26 6 393-400 (Pubitemid 14080810) (Pubitemid 14080810)
87. Decreased β-cell mass in Diabetes: Significance, mechanisms and Therapeutic implications. Donath MY, Halban PA Diabetologia 2004 47 3 581-589 (Pubitemid 38491259) (Pubitemid 38491259)
88. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY J Clin Invest 2002 110 6 851-860
89. Biologic basis for interleukin-1 in disease. Dinarello CA Blood 1996 87 6 2095-2147 (Pubitemid 26086851) (Pubitemid 26086851)
90. A urine inhibitor of interleukin 1 activity that blocks ligand-binding. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR J Immunol 1987 139 5 1546-1549 (Pubitemid 17151588) (Pubitemid 17151588)
91. The antiinflammatory Cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K Endocrinology 2008 149 5 2208-2218 (Pubitemid 351574505) (Pubitemid 351574505)
92. PReservation of β-cell function in autoantibody-positive youth with Diabetes. Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G, Marcovina S, Pihoker C Diabetes Care 2009 32 10 1839-1844
93. Lack of interleukin-1β decreases the severity of aTherosclerosis in ApoE-deficient mice. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M Arterioscler Thromb Vasc Biol 2003 23 4 656-660 (Pubitemid 36438080) (Pubitemid 36438080)
94. Effect of human recombinant Cytokines on the induction of macrophage procoagulant activity. Schwager I, Jungi TW Blood 1994 83 1 152-160 (Pubitemid 24016527) (Pubitemid 24016527)
95. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. Francis SE, Holden H, Holt CM, Duff GW J Mol Cell Cardiol 1998 30 2 215-223 (Pubitemid 28116301) (Pubitemid 28116301)
96. Inflammation in aTherosclerosis. Libby P Nature 2002 420 6917 868-874 (Pubitemid 36019640) (Pubitemid 36019640)
97. C-reactive protein: Risk marker or mediator in aTherothrombosis? Jialal I, Devaraj S, Venugopal SK Hypertension 2004 44 1 6-11 (Pubitemid 38823477) (Pubitemid 38823477)
98. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid aTherosclerosis. Hu Y, Tong GY, Xu W, Pan JJ, Ryan K, Yang RZ, Shuldiner AR, Gong DW, Zhu DL Diab Vas Dis Res 2009 6 4 262-268
99. Emerging role of interleukin-1 in cardiovascular diseases. Vicenova B, Vopalensky V, Burysek L, Pospisek M PHYSIOL Res 2009 58 4 481-498
100. IL-1 Cytokines in cardiovascular disease: Diagnostic, prognostic and Therapeutic implications. Apostolakis S, Vogiatzi K, Krambovitis E, Spandidos DA Cardiovasc Hematol Agents Med Chem 2008 6 2 150-158 (Pubitemid 351935022) (Pubitemid 351935022)
101. Local expRession of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS, Kim S, Jeon ES Circulation 2002 105 11 1278-1281 (Pubitemid 34260415) (Pubitemid 34260415)
102. Investigation of the effect of interleukin-1 receptor antagonist (IL-1Ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART study). Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, FlaTher MD, Lees B, Foley CE Trials 2008 9 8
103. Outcome after 40 years with rheumatoid arthritis: A prospective study of function, disease activity, and mortality. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ J Rheumatol SUPPL 2004 69 3-8 (Pubitemid 38327484) (Pubitemid 38327484)
104. Survival in rheumatoid arthritis: A population-based analysis of Trends over 40 years. Gabriel SE, Crowson CS, Kremers HM, Doran MF, TuResson C, O'Fallon WM, Matteson EL Arthritis Rheum 2003 48 1 54-58 (Pubitemid 36091647) (Pubitemid 36091647)
105. Quantitative analysis of Cytokine Gene expRession in rheumatoid arthritis. FiRestein GS, Alvaro-Gracia JM, Maki R J Immunol 1990 144 9 3347-3353 (Pubitemid 20146364) (Pubitemid 20146364)
106. Actual status of antiinterleukin-1 Therapies in rheumatic diseases. Geyer M, Muller-Ladner U Curr Opin Rheumatol 2010 22 3 246-251
107. Effectiveness of different DMARD co-Therapies in rituximab-treated rheumatoid arthritis patients: Results of a one-year follow up study from the CERRERA collaboration. Gabay C, Chatzidionysiou K, Nasonov E Ann Rheum Dis 2010 69 Suppl Abs OP0051
108. Abatacept demonstrates consistent safety and sustained improvements in efficacy through 4 years of open-label treatment in patients with an inadequate Response to anti-TNF Therapy. Genovese MC, Schiff M, Luggen ME, Le Bars M, Becker JC, Aranda R, Elegbe A, Cohen R, Dougados M Arthritis Rheum 2009 60 Suppl 10 Abs 1689
109. Association of glycaemia with macrovascular and microvascular complications of type 2 Diabetes (UKPDS 35): Prospective observational study. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR Br Med J 2000 321 7258 405-412 (Pubitemid 30609442) (Pubitemid 30609442)
110. Behcet's disease-A contemporary review. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J J Autoimmun 2009 32 3-4 178-188
111. Interleukin-1 mediates Alzheimer and Lewy body pathologies. Griffin WST, Liu L, Li YK, Mrak RE, Barger SW J Neuroinflamm 2006 3 5
112. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 Diabetes. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V et al Nat GeneT 2009 41 6 703-707
113. Localization of type 1 Diabetes susceptibility to the MHC class I Genes HLA-B and HLA-A. Nejentsev S, Howson JMM, Walker NM, Szeszko J, Field SF, Stevens HE, Reynolds P, Hardy M, King E, Masters J, Hulme J et al Nature 2007 450 7171 887-892 (Pubitemid 350231332) (Pubitemid 350231332)
114. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: A multicenter study. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P J Rheumatol 2005 32 7 1317-1323 (Pubitemid 40995389) (Pubitemid 40995389)
115. XOMA 052 phase 1 program. XOMA Ltd COMPANY PResENTATION 2009 July 14
116. Investor pResentation. XOMA Ltd COMPANY PResENTATION 2010 June
117. Phase I pharmacokinetic studies of XOMA 052, an anti-interleukin-1 β (IL-1b) regulatory monoclonal antibody, administered intravenously and subcutaneously to adult subjects with type 2 Diabetes. Der K, Xu L Aaps Natl Biotechnol Conf 2009 Abs M1082
118. The IL-1 family: Regulators of Immunity. Sims JE, Smith DE Nat Rev Immunol 2010 10 2 89-102
119. Interleukin-1 (IL-1) pathway. Weber A, Wasiliew P, Kracht M SCI Signaling 2010 3 105 cm1
120. Role of IL-1β in type 2 Diabetes. Dinarello CA, Donath MY, Mandrup-Poulsen T Curr Opin Endocrinol Diabetes Obes 2010 17 4 314-321
121. Interleukin-1-β in synovial-fluid is related to local disease-activity in rheumatoid-arthritis. Rooney M, Symons JA, Duff GW Rheumatol Int 1990 10 5 217-219
122. Combination Therapy with cyclosporine and methotrexate in severe rheumatoid-arthritis. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, Mckendry R, Tesser J, Baker P, Wells G N Engl J Med 1995 333 3 137-141
123. Interleukins in aTherosclerosis: Molecular pathways and Therapeutic potential. von der Thusen JH, Kuiper J, Van Berkel TJC, Biessen EAL Pharmacol Rev 2003 55 1 133-166 (Pubitemid 36268401) (Pubitemid 36268401)
124. Inhibition of tumor necrosis factor-α reduces aTherosclerosis in apolipoprotein E knockout mice. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S Arterioscler Thromb Vasc Biol 2004 24 11 2137-2142 (Pubitemid 39482442) (Pubitemid 39482442)
125. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study). Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC et al Am J Cardiol 2010 105 10 1371-1377
126. Epidemiology and Genetics of rheumatoid arthritis. Silman AJ Pearson JE ARTHRITIS Res 2002 4 Suppl 3 S265-S272
127. NHS: Rheumatoid arthritis-Treatment. NHS WEB SITE 2010 August 24
128. Interleukin-1. Stylianou E, Saklatvala J Int J Biochem Cel Biol 1998 30 10 1075-1079 (Pubitemid 28484829) (Pubitemid 28484829)
129. Anti-Cytokine Therapeutics and infections. Dinarello CA Vaccine 2003 21 S24-S34 (Pubitemid 36603315) (Pubitemid 36603315)
130. Tumor necrosis factor and tuberculosis. Lin PL, Plessner HL, Voitenok NN, Flynn JL J Invest Dermatol Symp Proc 2007 12 1 22-25 (Pubitemid 46763024) (Pubitemid 46763024)
131. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, Haak-Frendscho M, Masat L Mabs 2011 3 1 1-12
132. Induction of a chronic disease state in patients with sMoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM et al Mayo Clin Proc 2009 84 2 114-122
133. Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR, Voronov E, Martin MU, Dinarello CA, Apte RN Proc Natl Acad Sci USA 2010 107 6 2574-2579
134. NLRP3 inflammasomes are required for aTheroGenesis and activated by cholesterol crystals. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T et al Nature 2010 464 7293 1357-1361
135. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 Diabetes. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N et al Nat Immunol 2010 11 10 897-904
136. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: An update of the Oregon Drug Effectiveness Review Project. Thaler K, Chandiramani DV, Hansen RA, Gartlehner G Biologics 2009 3 485-498
137. Weight considerations in pharmacoTherapy for type 2 Diabetes. Cheng V, Kashyap SR J Obes 2011 2011 pii: 984245. Epub 2010 Sep 19
138. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Scheen AJ Diabetes Obes Metab 2010 12 8 648-658
139. ExpRession of Toll-like receptors in human aTherosclerotic lesions: A possible pathway for plaque activation. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ Circulation 2002 105 10 1158-1161 (Pubitemid 34225814) (Pubitemid 34225814)
140. Pathogen-mediated inflammatory aTherosclerosis is mediated in part via toll-like receptor 2-induced inflammatory Responses. Hayashi C, Madrigal AG, Liu X, Ukai T, Goswami S, Gudino CV, Gibson FC, Genco CA J Innate Immun 2010 2 4 334-343
141. Vascular cells contribute to aTherosclerosis by Cytokine-and innate-Immunity-related inflammatory mechanisms. Loppnow H, Werdan K, Buerke M Innate Immun 2008 14 2 63-87
142. ATP-binding membrane cassette transporter A1 (ABCA1): A possible link between inflammation and reverse cholesterol transport. Yin K, Liao DF, Tang CK Mol Med 2010 16 9-10 438-449
143. ABC transporters, aTherosclerosis and inflammation. Fitzgerald ML, Mujawar Z, Tamehiro N Atherosclerosis 2010 211 2 361-370
144. IL-1 antagonists. Kötter I, Horneff G Z Rheumatol 2010 69 7 581-593
145. Canakinumab for treatment of cryopyrin-associated periodic syndrome. Feist E, Burmester GR Expert Opin Biol Ther 2010 10 11 1631-1636